專任教授

吳俊穎 (Chun-Ying Wu)

個人簡歷
  • 職稱： 講座教授兼所長, 生物醫學資訊研究所 / 主任, 健康創新中心 / 主任, 醫學院微菌叢研究中心
  • 學歷： 臺大醫學博士、哈佛大學法學碩士暨公共衛生碩士
  • 辦公室：守仁樓三樓 R327-1 室
  • 電話：  886-2-28267155
  • Email：cywu4@nycu.edu.tw
  • 個人網頁：

研究領域
  • 研究興趣 (Research Interests)：
    • 健康大數據研究 (Health Big Data Research)
    • 消化系癌症轉譯研究 (Digestive Cancer Translational Research)
    • 腸道微生態研究 (Gut Microbiota Research)
    • 實證法學研究 (Empirical Legal Research)
    • 肝癌影像AI研究 (Liver cancer AI image research)
  • 代表性榮譽 (Representative honors)：
    • 2021年 傑出研究獎 (Outstanding Research Award, 2021)
    • 2018年 醫療典範獎 (Medical Model Award, 2018)
    • 2016年 國家新創獎 (National Innovation Award, 2016)
    • 2015年 傑出研究獎 (Outstanding Research Award, 2015)
    • 2015年 亞太新興領袖獎 (Asia Pacific Emerging Leadership Lecturer, 2015)
    • 2013年 國立陽明大學 教學績優琉璃獎座 (Best Teaching Lectureship Glass Award, NYMU, 2013)
    • Advances in Digestive Medicine主編 (Editor-in-Chief)
    • Journal of Gastroenterology & Hepatology副主編 (Associate Editor)
    • Gut編輯委員 (Editor)
  • 代表性專利 (Representative Patents)：
    • 他丁類化合物用於治療胃癌之用途2017
    • 腸道微菌療法、其所使用之組合物及該組合物之製備方法2017、2018
    • 用於檢測或/及定量Ｂ型肝炎病毒之平台及其方法2017
    • 胃癌生物標幟物及其用途，以及與胃癌相關之檢測方法2015

研究著作
  • 代表性論文 (Representative Papers)：
    • Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma following liver resection.
      JAMA 2012 Nov 12, 308(18): 1906-13 (SCI, IF 120.7, 3/168; Medicine, General & Internal).
    • Wu CY, Wu MS, Kuo KN, Chen YJ, Wang CB, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients.
      J Clin Oncol 2010 Jun; 28(18): 2952-7. (SCI, IF 45.3, 7/242; Oncology).
    • Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, Wu CY*. Association of daily aspirin therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B.
      JAMA Intern Med 2019 May 1; 179(5): 633-40 (SCI, IF 39.0, 7/168; Medicine, General & Internal).
    • Yeo YH, Ho HJ, Yang HI…, Wu CY*, Nguyen MH. The HBsAg seroclearance rate and predictors in adults with chronic hepatitis B: a systematic review and meta-analysis.
      Gastroenterology 2019 Feb; 156(3): 635-46 (SCI, IF 29.4, 3/93; Gastroenterology & Hepatology).
    • Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC. Association of nucleos(t)ide analogues therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. (SCI, IF 29.4, 3/93; Gastroenterology & Hepatology).
    • Wu CY, Chan FK, Wu MS, Kuo KN, Wang CB, Tsao CR, Lin JT. Histamine-2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.
      Gastroenterology 2010 Oct; 139(4): 1165-71 (SCI, IF 29.4, 3/93; Gastroenterology & Hepatology).
    • Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease.
      Gastroenterology 2009 Nov; 137(5):1641-8 (SCI, IF 29.4, 3/93; Gastroenterology & Hepatology).
    • Wu CY*, Liang LL, Ho HJ, Hsu CT, Hsu HT, Ao CK, Wu CY, Lin YH, Chuang YF, Hsu YC, Chen YJ, Ng SC. Association between physical fitness and risk of inflammatory bowel diseases in children and adolescents: a nationwide cohort.
      JAMA Ped 2023 Jun 1; 177(6): 608-16 (SCI, IF 26.1; 2/130; Pediatrics)
    • Hsu YC, Yip TCF, Ho HJ, Wong VWS, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GLH, Wu CY*. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
      J Hepatol 2018 Aug; 69(2): 278-85 (SCI, IF 25.7, 4/93; Gastroenterology & Hepatology).
    • Wu CY*, Ho HJ, Wu CY, Chen YJ, Lee TY, Hsu YC, Lin JT. Association between proton pump inhibitor use and mortality in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor.
      Gut 2021 Sep 9; gutjnl-2020-321932 (SCI, IF 24.5, 5/93; Gastroenterology & Hepatology).
    • Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM, Wu CY*. First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis.
      Gut 2018 Jan; 67(1): 20-7 (SCI, IF 24.5, 5/93; Gastroenterology & Hepatology).
    • Wu CY, Hsu YC, Ho HJ, Chen YJ, Lee TY, Lin JT. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study.
      Gut 2016 Apr; 65(4): 693-701 (SCI, IF 24.5, 5/93; Gastroenterology & Hepatology).
    • Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY*. Association between antiviral therapy and extrahepatic outcomes in patients with hepatitis C virus infection.
      Gut 2015 Mar;64(3): 495-503 (SCI, IF 24.5, 5/93; Gastroenterology & Hepatology).
    • Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, Lin JH, Wu CY* Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.
      Gut 2013 Apr; 62(4): 606-15 (SCI, IF 24.5, 5/93; Gastroenterology & Hepatology).
    • Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Long term peptic ulcer rebleeding risk estimation in patients undergoing haemodialysis: a 10-year nationwide cohort study.
      Gut 2011 Aug; 60(8): 1038-42 (SCI, IF 24.5, 5/93; Gastroenterology & Hepatology).
    • Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH, Lin JT. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.
      Gut 2007 Jun;56(6):782-9 (SCI, IF 24.5, 5/93; Gastroenterology & Hepatology).
  • 法律專書 (Law Textbook)：
    • 吳俊穎：現行醫療鑑定制度介紹及改革建議(ISBN: 978-986-255-542-2) (元照出版社，2014年12月出版)。
    • 吳俊穎、陳榮基、楊增暐、翁慧卿、賴惠蓁：實證法學：醫療糾紛的全國性實證研究(元照出版社，2014年8月出版)。
    • 吳俊穎、陳榮基、楊增暐、賴惠蓁、吳佳勳：清官難斷醫務事？醫療過失責任與醫療糾紛鑑定(ISBN: 978-986-255-187-5) (元照出版社，2013年7月二版)。
    • 吳俊穎、賴惠蓁、陳榮基：法官，我說明夠了嗎？醫師說明義務法院判決評析(ISBN: 978-957-9201-45-2) (橘井出版社，2010年7月出版)。